相关实验视频
Updated: Jul 7, 2025

06:55
Ileectomy-induced Bile Overaccumulation in Mouse Intestine
Published on: August 21, 2017
9.5K
丁酸盐作为5-HT载体的阳性全调节剂,可降低5-HT在阴茎中的可用性
Jieling Cai1,2, Jamie Cheung1,2, Samson W M Cheung1,2
1State Key Laboratory of Pharmaceutical Biotechnology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
British journal of pharmacology
|December 22, 2023
概括
高脂肪饮食 (HFD) 可以通过增加肠道细菌产生酸盐来减少放射治疗的副作用. 这抑制了血清素 (5-HT) 水平,有可能缓解癌症患者的胃肠道痛苦.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
背景情况:
- 放射治疗可能会导致胃肠道的痛苦,因为肠道微生物群的破坏.
- 血清素 (5-HT) 在放射治疗诱导的吐中起作用,而外围的5-HT来源于肠道上皮质.
- 肠道微生物群对肠道5-HT可用性的影响尚未完全理解.
研究的目的:
- 研究肠道微生物群在调节肠道5-HT可用性的作用.
- 探索饮食诱导的微生物组变化对5-HT水平的影响.
- 为了确定饮食干预对辐射诱导的胃肠道疾病的治疗潜力.
主要方法:
- 利用放射治疗的小鼠模型与来自不同饮食的捐赠者的便微生物移植.
- 在对5-HT吸收的机理学研究中使用了小鼠皮质器官.
- 通过一项小规模人类研究验证的结果,该研究将微生物代谢物与血清5-HT和BMI相关联.
主要成果:
- 短期高脂肪饮食 (HFD) 促进了肠道细菌的丁酸盐生产.
- 照射过的小鼠具有HFD诱导的微生物组,表现出最低的内5-HT水平.
- 丁酸盐被确定为血清素转运体 (SERT) 的积极全调节剂,增加了有机体中5-HT的吸收. 人类数据显示便酸盐/酸盐和血清5-HT之间存在负面关联.
结论:
- 短期的HFD可以通过增加丁酸盐来减轻放射治疗诱导的胃肠道反应,这抑制了局部的5-HT水平.
- 这种饮食方法可以为接受放射治疗的癌症患者提供能量来源.
- 研究结果表明,一种潜在的饮食策略可以控制治疗副作用.
相关概念视频
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
264
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
264
Drugs for Treatment of Constipation-Predominant IBS
176
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
176
Drugs for Treatment of Diarrhea-Predominant IBS
179
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
179
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
213
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
213
Carrier-Mediated Transport
441
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
441

